Sanofi (NASDAQ:SNY - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Investors bought 2,521 put options on the company. This represents an increase of approximately 35% compared to the average volume of 1,872 put options.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in SNY. Allworth Financial LP lifted its position in shares of Sanofi by 2.7% during the 2nd quarter. Allworth Financial LP now owns 9,233 shares of the company's stock valued at $394,000 after buying an additional 243 shares in the last quarter. Euro Pacific Asset Management LLC grew its stake in shares of Sanofi by 0.6% during the 3rd quarter. Euro Pacific Asset Management LLC now owns 46,121 shares of the company's stock valued at $1,902,000 after acquiring an additional 253 shares during the period. Rothschild Investment LLC grew its stake in shares of Sanofi by 7.8% during the 3rd quarter. Rothschild Investment LLC now owns 3,847 shares of the company's stock valued at $159,000 after acquiring an additional 277 shares during the period. Focused Alpha LLC grew its stake in shares of Sanofi by 4.5% during the 3rd quarter. Focused Alpha LLC now owns 6,553 shares of the company's stock valued at $270,000 after acquiring an additional 281 shares during the period. Finally, Intrua Financial LLC increased its holdings in Sanofi by 6.4% in the 3rd quarter. Intrua Financial LLC now owns 5,100 shares of the company's stock worth $210,000 after acquiring an additional 309 shares in the last quarter. Institutional investors own 14.03% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on SNY shares. Wolfe Research assumed coverage on shares of Sanofi in a research note on Friday, October 9th. They issued a "peer perform" rating for the company. Royal Bank Of Canada initiated coverage on shares of Sanofi in a research report on Tuesday, September 8th. They set a "sector perform" rating for the company. Weiss Ratings raised shares of Sanofi from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday. JPMorgan Chase & Co. restated a "neutral" rating on shares of Sanofi in a report on Thursday, October 1st. Finally, Berenberg Bank restated a "buy" rating on shares of Sanofi in a report on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and twelve have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $53.00.
Check Out Our Latest Stock Analysis on Sanofi
Sanofi Stock Down 2.4%
Sanofi stock traded down $1.14 during mid-day trading on Thursday, reaching $45.98. The stock had a trading volume of 2,928,955 shares, compared to its average volume of 3,488,053. The company has a market capitalization of $111.48 billion, a price-to-earnings ratio of 22.80, a PEG ratio of 1.30 and a beta of 0.31. The company has a 50-day moving average price of $42.94 and a two-hundred day moving average price of $44.40. Sanofi has a one year low of $39.07 and a one year high of $50.60. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.12 and a quick ratio of 0.27.
Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.56 by $0.48. The company had revenue of $17.25 billion for the quarter, compared to the consensus estimate of $14.30 billion. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. Sanofi's revenue for the quarter was up 16.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.91 EPS. On average, analysts expect that Sanofi will post 5.07 EPS for the current fiscal year.
About Sanofi
(
Get Free Report)
Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company's portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.